F. Charles Brunicardi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
F. Charles Brunicardi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Francesco John DeMayo
Reproductive and Developmental Biology Laboratory National Institute of Environmental Health Sciences Research Triangle Park North Carolina USA
1 shared publication - Manas K. Ray
Baylor College of Medicine, Department of Surgery, Houston, TX 77030, USA
1 shared publication Shawn P. Fagan
Departments of Surgery, One Baylor Plaza, Baylor College of Medicine, Houston
1 shared publicationStefan Moldovan
Departments of Surgery, One Baylor Plaza, Baylor College of Medicine, Houston
1 shared publication
Latest Publications
- 1 June 1999
- Published by Springer Nature in International journal of pancreatology
- Vol. 25 (3) , 157-163
Development of a transgenic mouse model using rat insulin promoter to drive the expression of CRE recombinase in a tissue-specific manner
Summary Background Tissue-specific ablation of a gene using the Cre-loxP system has been used as an important tool to define its role, in addition to the total ablation, to avoid the embryonic lethality in case of wide expression of the target gene. Methods The RIP-Cre genetic construct was generated by standard subcloning techniques and microinjected into one cell embryo to develop the transgenic mouse line. Transgenic mice were screened by polymerase chain reaction (PCR) using DNA isolated from tell digestion. Tissue specificity of RIP was demonstrated by transient transfection of RIP-lacZ construct to NIT-1 cells (mouse insulinoma cell line) in vitro. Results The 448 nucleotides of RIP were sufficient for β-cell specific expression of the reporter gene as evidenced by the presence of blue color in the nucleus of NIT-1 cells. Isolated RIP-Cre transgene was microinjected, and PCR screening identified two independent lines of transgenic mice. Tissue specificity of RIP was demonstrated by reverse transcriptase polymerase chain reaction (RT-PCR) using the islet RNA from the transgenic mice. Conclusion We have established a tissue-specific transgenic mouse model using Cre recombinase linked to rat insulin promoter (RIP) to drive the expression of the reporter gene specifically in the β-cells. The RIP-Cre transgenic mice will allow β-cell specific ablation of target gene(s) to define its role in the regulation of islet physiology.
- 1 June 1999
- Published by Springer Nature in International journal of pancreatology
- Vol. 25 (3) , 157-163
Development of a transgenic mouse model using rat insulin promoter to drive the expression of CRE recombinase in a tissue-specific manner
Summary Background Tissue-specific ablation of a gene using the Cre-loxP system has been used as an important tool to define its role, in addition to the total ablation, to avoid the embryonic lethality in case of wide expression of the target gene. Methods The RIP-Cre genetic construct was generated by standard subcloning techniques and microinjected into one cell embryo to develop the transgenic mouse line. Transgenic mice were screened by polymerase chain reaction (PCR) using DNA isolated from tell digestion. Tissue specificity of RIP was demonstrated by transient transfection of RIP-lacZ construct to NIT-1 cells (mouse insulinoma cell line) in vitro. Results The 448 nucleotides of RIP were sufficient for β-cell specific expression of the reporter gene as evidenced by the presence of blue color in the nucleus of NIT-1 cells. Isolated RIP-Cre transgene was microinjected, and PCR screening identified two independent lines of transgenic mice. Tissue specificity of RIP was demonstrated by reverse transcriptase polymerase chain reaction (RT-PCR) using the islet RNA from the transgenic mice. Conclusion We have established a tissue-specific transgenic mouse model using Cre recombinase linked to rat insulin promoter (RIP) to drive the expression of the reporter gene specifically in the β-cells. The RIP-Cre transgenic mice will allow β-cell specific ablation of target gene(s) to define its role in the regulation of islet physiology.